Quest Pharmatech Inc.TSXV: QPT

Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Nov 18, 2015 at 2:30 PM UTC · Issued by Quest PharmaTech Inc.

Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: madi@questpharmatech.com, Internet: www.questpharmatech.comCopyright CNW Group 2015